Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients with Chronic Hepatitis C Virus Infection

Clinical Infectious Diseases

Volumn 66, Issue 2, 2018, Pages 289-292

  Liu, Chen Hua ^a   Chen, Yih Sharng ^a   Wang, Sheoi Shen ^a,c,d   Liu, Chun Jen ^a   Su, Tung Hung ^a   Yang, Hung Chih ^a   Hong, Chun Ming ^a   Chen, Pei Jer ^a   Chen, Ding Shinn ^a,b   Kao, Jia Horng ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b GENOMICS RESEARCH CENTER   (Taiwan)

^c FU JEN CATHOLIC UNIVERSITY HOSPITAL   (Taiwan)

^d FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

direct acting antiviral agent; heart transplantation; hepatitis C virus

Indexed keywords

ALANINE AMINOTRANSFERASE; CYCLOSPORINE; DACLATASVIR; EVEROLIMUS; LEDIPASVIR PLUS SOFOSBUVIR; MYCOPHENOLATE MOFETIL; PREDNISONE; RAPAMYCIN; SOFOSBUVIR; TACROLIMUS; VIRUS RNA; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; BMS-790052; FLUORENE DERIVATIVE; IMIDAZOLE DERIVATIVE; LEDIPASVIR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DUODENAL ULCER BLEEDING; ENDOSCOPIC THERAPY; FEMALE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; MALE; MIDDLE AGED; PRIORITY JOURNAL; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; ADVERSE DRUG REACTION; ADVERSE EVENT; COMBINATION DRUG THERAPY; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; YOUNG ADULT;

ADULT; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FLUORENES; HEART TRANSPLANTATION; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85040562078     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix787     Document Type: Article

References (16)

1. Fagiuoli S, Minniti F, Pevere S, et al. HBV and HCV infections in heart transplant recipients. J Heart Lung Transplant 2001; 20:718-24.
2. Lunel F, Cadranel JF, Rosenheim M, et al. Hepatitis virus infections in heart transplant recipients: epidemiology, natural history, characteristics, and impact on survival. Gastroenterology 2000; 119:1064-74.
3. Lee I, Localio R, Brensinger CM, et al. Decreased post-Transplant survival among heart transplant recipients with pre-Transplant hepatitis C virus positivity. J Heart Lung Transplant 2011; 30:1266-74.
4. Gasink LB, Blumberg EA, Localio AR, Desai SS, Israni AK, Lautenbach E. Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. JAMA 2006; 296:1843-50.
5. Kumar S, Deo SV, Altarabsheh SE, et al. Effect of hepatitis C positivity on survival in adult patients undergoing heart transplantation (from the United Network for organ sharing database). Am J Cardiol 2016; 118:132-7.
6. Stepanova M, Locklear T, Rafiq N, Mishra A, Venkatesan C, Younossi ZM. Longterm outcomes of heart transplant recipients with hepatitis C positivity: The data from the U.S.Transplant registry. Clin Transplant 2016; 30:1570-7.
7. Belga S, Doucette KE. Hepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizon. World J Gastroenterol 2016; 22:1650-63.
8. Trakroo S, Qureshi K. Successful treatment of chronic hepatitis C infection with direct-Acting antivirals in a heart transplant recipient: A case report. Transplant Proc 2015; 47:2295-7.
9. Casanovas T, Roca J, Niub J. Successful treatment of hepatitis C virus infection combining daclatasvir and simeprevir in a heart transplant recipient with decompensated cirrhosis. J Heart Lung Transplant 2016; 35:949-51.
10. Maasoumy B, Vermehren J, Welker MW, et al. Clinical value of on-Treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. J Hepatol 2016; 65:473-82.
11. Liu CH, Chen YS, Wang SS, Kao JH. Treatment of de novo hepatitis C virus-related fibrosing cholestatic hepatitis after orthotopic heart transplantation by ledipasvir and sofosbuvir. J Formos Med Assoc 2017; 116:407-9.
12. Coilly A, Samuel D. Pros and Cons: Usage of organs from donors infected with hepatitis C virus-revision in the direct-Acting antiviral era. J Hepatol 2016; 64:226-31.
13. Jacobson IM, Gordon SC, Kowdley KV, et al.; POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368:1867-77.
14. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878-87.
15. Zeuzem S, Dusheiko GM, Salupere R, et al.; VALENCE Investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370:1993-2001.
16. Mangia A, Arleo A, Copetti M, et al. The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin. Liver Int 2016; 36:971-6.